iShares Biotechnology ETF (IBB)

NASDAQ: IBB · IEX Real-Time Price · USD
-0.60 (-0.44%)
At close: May 17, 2024, 4:00 PM
-0.38 (-0.28%)
After-hours: May 17, 2024, 6:53 PM EDT
Assets $7.28B
Expense Ratio 0.45%
PE Ratio 17.83
Shares Out 52.95M
Dividend (ttm) $0.41
Dividend Yield 0.30%
Ex-Dividend Date Mar 21, 2024
Payout Ratio 5.34%
1-Year Return +5.69%
Volume 837,890
Open 137.00
Previous Close 137.29
Day's Range 136.09 - 137.44
52-Week Low 111.83
52-Week High 141.16
Beta 0.87
Holdings 223
Inception Date Feb 5, 2001

About IBB

Fund Home Page

The iShares Biotechnology ETF (IBB) is an exchange-traded fund that is based on the NYSE Biotechnology index. The fund tracks the performance of a modified market-cap-weighted index of US biotechnology companies listed on US exchanges. IBB was launched on Feb 5, 2001 and is issued by BlackRock.

Asset Class Equity
Category Health
Region North America
Stock Exchange NASDAQ
Ticker Symbol IBB
ETF Provider BlackRock
Index Tracked NYSE Biotechnology

Top 10 Holdings

52.33% of assets
Name Symbol Weight
Amgen Inc. AMGN 9.27%
Vertex Pharmaceuticals Incorporated VRTX 8.45%
Regeneron Pharmaceuticals, Inc. REGN 8.08%
Gilead Sciences, Inc. GILD 7.59%
Moderna, Inc. MRNA 4.37%
IQVIA Holdings Inc. IQV 4.14%
Biogen Inc. BIIB 3.26%
Mettler-Toledo International Inc. MTD 3.18%
Waters Corporation WAT 2.09%
BioNTech SE BNTX 1.89%
View More Holdings


Ex-Dividend Amount Pay Date
Mar 21, 2024 $0.12599 Mar 27, 2024
Dec 20, 2023 $0.12396 Dec 27, 2023
Sep 26, 2023 $0.15316 Oct 2, 2023
Jun 7, 2023 $0.00621 Jun 13, 2023
Mar 23, 2023 $0.06456 Mar 29, 2023
Dec 13, 2022 $0.1014 Dec 19, 2022
Full Dividend History


Fighting Obesity Using ETFs

Weight loss has long been a challenge for many people, me included. Indeed, there are an estimated 1 billion individuals living with obesity, and the Obesity World Atlas estimates this could rise to 1...

Other symbols: HRTSXLV
5 days ago - ETF Trends

This weight-loss ETF has performed well in its first five months. How does it compare with cheaper alternatives?

A new exchange-traded fund needs an edge to attract investors. This might be its industry focus — a tall order in a crowded market with ETFs covering just about any industry you can imagine.

5 weeks ago - Market Watch

Biotech's Next Gold Rush: Weight-Loss Drugs

Biotech's next gold rush is weight-loss drugs. There is a dominance of NVO and LLY in this space for now, notes Rahul Jasuja.

Other symbols: LLYNVO
6 weeks ago - Schwab Network

Navigating the big run in biotech

The 'Halftime Report' Investment Committee debates the upside potential in the biotech space.

Other symbols: XBI
3 months ago - CNBC Television

Health care's underperformance last year sets it up well for 2024, says Mara Goldstein

Mara Goldstein, Biotech Analyst at Mizuho, discusses health care's outperformance this week.

Other symbols: XLV
3 months ago - CNBC Television

Dr. Scott Gottlieb talks Big Pharma's buying spree

Dr. Scott Gottlieb, joins 'Closing Bell' to discuss the government's regulation on the pharmaceutical industry.

Other symbols: XBI
5 months ago - CNBC Television

Wedbush's Laura Chico talks biotech investing in 2024

Laura Chico, Wedbush Biotech Analyst, joins 'Closing Bell Overtime' to talk investing in biotech.

5 months ago - CNBC Television

Buy or bail on biotech: Here's what you need to know

Biotech is up double digits this month. Piper Sandler says that the sector is breaking out.

Other symbols: XBI
5 months ago - CNBC Television

Biotech Stocks Are Breaking Out—and They Show No Sign of Slowing Down

Shares have gotten a boost from the Fed and from M&A.

Other symbols: XBI
5 months ago - Barrons

Wells Fargo's top pharma picks for 2024

Mohit Bansal, Wells Fargo Analyst, joins 'Closing Bell: Overtime' to discuss Wells Fargo's pharma picks for 2024.

5 months ago - CNBC Television

We see Big Pharma going after smaller biotechs in 2024, says Jefferies' Michael Yee

Michael Yee, Jefferies senior biotech analyst, joins 'Squawk Box' to discuss the state of the biotech industry, impact of interest rate environment on the sector, growth outlook in 2024, obesity drug ...

Other symbols: MRKMRNAPFE
5 months ago - CNBC Television

How to Find the Best Biotech ETFs

The best biotech ETFs allow investors a diversified way to play the volatile biotechnology industry. Here's how to find them.

Other symbols: ARKGXBI
7 months ago - Kiplinger

Goldman Sachs' Chris Shibutani talks his top biotech picks including Eli Lilly and Pfizer

Chris Shibutani, Goldman Sachs Senior Analyst, joins 'Closing Bell Overtime' to talk his top picks in the biotech sectors.

Other symbols: LLYPFEXBI
8 months ago - CNBC Television

Final Trades: Abbvie, Thermo Fisher & more

The "Halftime Report" traders give their top picks to watch for the second half.

Other symbols: ABBVTMO
1 year ago - CNBC Television

Regional banks pace decliners, as biotech deals lift Seagen and Provention Bio

Here are some of the biggest movers on Monday with banks firmly in focus after federal regulators stepped into protect deposits at fallen bank SVB.

Other symbols: KREXBI
1 year ago - Market Watch

SVB fallout: The impacts on the biotech sector

CNBC's Meg Tirrell reports on how the SVB fallout could impact biotech investors.

Other symbols: SIVBXBI
1 year ago - CNBC Television

The Recent Bullish Trend in IBB, XBI Looks Shaky

Rising interest rates taking steam from rally that powered in IBB and XBI. 

Other symbols: XBI
1 year ago - ETFcom

Analysis: Biotech IPOs to bloom with spotlight on startups with human trial data

Initial public offerings by small private biotech companies are poised to stage a comeback later in 2023 as the pace of interest rate hikes slows, but tougher economic conditions will make investors m...

Other symbols: XBI
1 year ago - Reuters

Pharmaceutical companies losing patent protection as competition grows

The Wall Street Journal's Jared Hopkins joins 'Power Lunch' to discuss biotech patent protection duration, competition coming to the pharmaceutical industry and pharmaceutical M&A plans.

Other symbols: ABBVMRKNVSPFE
1 year ago - CNBC Television

There's a crop of great biotech companies ready to be acquired, says MPM's Christiana Bardon

Dr. Christiana Bardon, co-managing partner of MPM's BioImpact Capital, joins 'The Exchange' to discuss tailwinds in the pharmaceutical and biotech sector, innovation in obesity drugs, and acquisition ...

Other symbols: XBI
1 year ago - CNBC Television

Why Biotech Is Poised for a Recovery This Year

Pharma and biotech stocks moved in opposite directions last year, but fortunes are shifting.

Other symbols: XBI
1 year ago - WSJ

Subversive Launches ETF to Focus on Mental Health

The debut highlights the lack of funds focused on the area.

Other symbols: PJP
1 year ago - ETFcom

JPMorgan's bullish call on biopharma

The "Halftime Report" traders debate the biggest analyst calls of the day.

Other symbols: ABBVLLYMRKZTS
1 year ago - CNBC Television

Final Trades: IBB, META, TSM & LVS

The traders make their final trades of the week. With CNBC's Dominic Chu and the Fast Money traders, Tim Seymour, Courtney Garcia, Steve Grasso and Jeff Mills.

Other symbols: METATSMLVS
1 year ago - CNBC Television

ETFs Find a Role in a Long-Term Portfolio

Albion Financial's Jason Ware sees funds as mainstays in ‘core-satellite' planning.

Other symbols: IJRXLE
1 year ago - ETFcom